ATE354592T1 - Vegf-antagonisten zur behandlung von diabetes - Google Patents

Vegf-antagonisten zur behandlung von diabetes

Info

Publication number: ATE354592T1
Authority: AT; Austria
Prior art keywords: vegf; treating diabetes; vegf antagonists; blocking; mediated activity
Prior art date: 2003-03-28

Application number

AT04758372T

Other languages

English (en)

Inventor

Mark W Sleeman

Stanley J Wiegand

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-28

Filing date

2004-03-26

Publication date

2007-03-15

2004-03-26 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE354592T1 publication Critical patent/ATE354592T1/de

Links

102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 6
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract 6
239000005557 antagonist Substances 0.000 title abstract 2
206010012601 diabetes mellitus Diseases 0.000 title abstract 2
230000000903 blocking effect Effects 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Immunology (AREA)
Toxicology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AT04758372T 2003-03-28 2004-03-26 Vegf-antagonisten zur behandlung von diabetes ATE354592T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US45879003P	2003-03-28	2003-03-28

Publications (1)

Publication Number	Publication Date
ATE354592T1 true ATE354592T1 (de)	2007-03-15

Family

ID=33131825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04758372T ATE354592T1 (de)	2003-03-28	2004-03-26	Vegf-antagonisten zur behandlung von diabetes

Country Status (16)

Country	Link
US (1)	US7052691B2 (de)
EP (1)	EP1608685B1 (de)
JP (2)	JP4730909B2 (de)
AT (1)	ATE354592T1 (de)
AU (1)	AU2004226417B2 (de)
BR (1)	BRPI0408749B1 (de)
CA (1)	CA2519787C (de)
CY (1)	CY1106530T1 (de)
DE (1)	DE602004004883T2 (de)
DK (1)	DK1608685T3 (de)
ES (1)	ES2278333T3 (de)
MX (1)	MXPA05008972A (de)
PL (1)	PL1608685T3 (de)
PT (1)	PT1608685E (de)
SI (1)	SI1608685T1 (de)
WO (1)	WO2004087206A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005267741A1 (en) *	2004-07-30	2006-02-09	Regeneron Pharmaceuticals, Inc.	Methods of treating type I diabetes by blocking VEGF-mediated activity
ES2633574T3 (es)	2005-03-25	2017-09-22	Regeneron Pharmaceuticals, Inc.	Formulaciones de antagonistas de VEGF
CA2654510C (en)	2006-06-16	2015-03-17	Regeneron Pharmaceuticals, Inc.	Vegf antagonist formulations suitable for intravitreal administration
ES2345596B1 (es) *	2009-03-26	2011-07-13	Fundacion Progreso Y Salud	Composicion para la prevencion o el tratamiento de la diabetes mellitus.
US20100330098A1 (en) *	2009-06-29	2010-12-30	Kuo Calvin J	Methods to regulate glucose metabolism
KR20190049934A (ko)	2011-01-13	2019-05-09	리제너론 파아마슈티컬스, 인크.	혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar)	2011-04-26	2018-09-16	Sanofi Sa	تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
MX368442B (es)	2014-01-25	2019-10-02	Chengdu Kanghong Biotechnologies Co Ltd	Proteína de fusión que inhibe angiogénesis o crecimiento y uso de la misma.
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
EA035674B1 (ru)	2014-07-18	2020-07-24	Санофи	Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
KR20250057128A (ko)	2015-12-30	2025-04-28	코디악 사이언시스 인코포레이티드	항체 및 이의 접합체
ITUB20169928A1 (it) *	2016-01-12	2017-07-12	Medical And Biotechnological Services In Sigla M B S Srl	Formulazioni farmaceutiche per il trattamento del diabete
HUE059827T2 (hu)	2017-11-30	2023-01-28	Regeneron Pharma	VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
EP3758737A4 (de)	2018-03-02	2022-10-12	Kodiak Sciences Inc.	Il-6-antikörper und fusionskonstrukte und konjugate davon
CA3157509A1 (en)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Methods of treating an eye disorder
AU2021268026A1 (en)	2020-05-08	2023-01-19	Regeneron Pharmaceuticals, Inc.	VEGF traps and mini-traps and methods for treating ocular disorders and cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9410533D0 (en) *	1994-05-26	1994-07-13	Lynxvale Ltd	In situ hybridisation and immuno-Chemical localisation of a growth factor
US6342219B1 (en) *	1999-04-28	2002-01-29	Board Of Regents, The University Of Texas System	Antibody compositions for selectively inhibiting VEGF
CN101433715B (zh) *	1999-06-08	2013-04-17	里珍纳龙药品有限公司	具有改善的药物动力学特性的修饰嵌合多肽
US6833349B2 (en) *	1999-06-08	2004-12-21	Regeneron Pharmaceuticals, Inc.	Methods of treating inflammatory skin diseases

2004
- 2004-03-26 WO PCT/US2004/009246 patent/WO2004087206A2/en not_active Ceased
- 2004-03-26 AU AU2004226417A patent/AU2004226417B2/en not_active Ceased
- 2004-03-26 BR BRPI0408749A patent/BRPI0408749B1/pt not_active IP Right Cessation
- 2004-03-26 US US10/811,170 patent/US7052691B2/en not_active Expired - Lifetime
- 2004-03-26 AT AT04758372T patent/ATE354592T1/de active
- 2004-03-26 EP EP04758372A patent/EP1608685B1/de not_active Expired - Lifetime
- 2004-03-26 PL PL04758372T patent/PL1608685T3/pl unknown
- 2004-03-26 PT PT04758372T patent/PT1608685E/pt unknown
- 2004-03-26 CA CA2519787A patent/CA2519787C/en not_active Expired - Fee Related
- 2004-03-26 DK DK04758372T patent/DK1608685T3/da active
- 2004-03-26 ES ES04758372T patent/ES2278333T3/es not_active Expired - Lifetime
- 2004-03-26 SI SI200430312T patent/SI1608685T1/sl unknown
- 2004-03-26 MX MXPA05008972A patent/MXPA05008972A/es active IP Right Grant
- 2004-03-26 DE DE602004004883T patent/DE602004004883T2/de not_active Expired - Lifetime
- 2004-03-26 JP JP2006509325A patent/JP4730909B2/ja not_active Expired - Fee Related
2007
- 2007-04-19 CY CY20071100538T patent/CY1106530T1/el unknown
2010
- 2010-10-20 JP JP2010235790A patent/JP2011037894A/ja active Pending

Also Published As

Publication number	Publication date
BRPI0408749A (pt)	2006-03-28
PL1608685T3 (pl)	2007-07-31
JP2011037894A (ja)	2011-02-24
AU2004226417A1 (en)	2004-10-14
EP1608685A2 (de)	2005-12-28
DE602004004883D1 (de)	2007-04-05
US20040213787A1 (en)	2004-10-28
HK1080092A1 (en)	2006-04-21
SI1608685T1 (sl)	2007-08-31
ES2278333T3 (es)	2007-08-01
CA2519787A1 (en)	2004-10-14
JP4730909B2 (ja)	2011-07-20
JP2006521397A (ja)	2006-09-21
CA2519787C (en)	2012-06-05
EP1608685B1 (de)	2007-02-21
MXPA05008972A (es)	2005-11-04
DK1608685T3 (da)	2007-06-11
BRPI0408749B1 (pt)	2016-10-04
PT1608685E (pt)	2007-05-31
US7052691B2 (en)	2006-05-30
WO2004087206A3 (en)	2004-12-16
WO2004087206A2 (en)	2004-10-14
DE602004004883T2 (de)	2007-11-15
AU2004226417B2 (en)	2009-01-22
CY1106530T1 (el)	2012-01-25

Legal Events

Date

Code

Title

Description

2007-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1608685

Country of ref document: EP

Publication	Publication Date	Title
ATE354592T1 (de)	2007-03-15	Vegf-antagonisten zur behandlung von diabetes
ATE513550T1 (de)	2011-07-15	Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
ATE451930T1 (de)	2010-01-15	Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
NO20070506L (no)	2007-02-14	Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer.
DE60210093D1 (de)	2006-05-11	Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
ATE406351T1 (de)	2008-09-15	Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
ATE499097T1 (de)	2011-03-15	Monozyklische heterozyklen als kinase-hemmer
EA200870029A1 (ru)	2008-10-30	Способ применения антагонистов il-6 с ингибиторами протеасом
ATE506456T1 (de)	2011-05-15	Verfahren zur behandlung von lentivirusinfektionen
EA200601553A1 (ru)	2006-12-29	Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
ATE419253T1 (de)	2009-01-15	Inhibitoren von thienopyridin- und furopyridinkinase
ATE404574T1 (de)	2008-08-15	Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
ATE554087T1 (de)	2012-05-15	Neue kinaseinhibitoren
DE60039783D1 (de)	2008-09-18	Lfa-1 antagonisten und tnf-alpha antagonisten zur
ATE555803T1 (de)	2012-05-15	Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE404190T1 (de)	2008-08-15	N-aryl-n'-arylcycloalkyl-harnstoff als mch antagonisten zur behandlung von fettleibigkeit
MX2007001241A (es)	2007-07-11	Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf.
BRPI0718469A2 (pt)	2014-01-21	Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
ATE359283T1 (de)	2007-05-15	Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DE60329326D1 (de)	2009-10-29	Tace inhibitoren
DE502005007105D1 (de)	2009-05-28	4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü-pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
EA200800766A1 (ru)	2008-06-30	Ингибиторы pi3k для лечения эндометриоза
TW200716132A (en)	2007-05-01	Novel chemical compounds
ATE491952T1 (de)	2011-01-15	Screening auf inhibitoren des eindringens von hepatitis-c-virus
ATE333869T1 (de)	2006-08-15	Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen